Key facts
- This page summarizes Mark E. Saad's Form 4 filing for Axsome Therapeutics, Inc. (AXSM).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Sep 2024, 19:00.
Mark E. Saad - 11 Sep 2024 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)
- Reporting relationship
- Director
- Issuer ticker
- AXSM
- Reported as of
- 11 Sep 2024
- Net transaction value
- -$965,442
- SEC form
- 4
- Accepted by SEC
- 11 Sep 2024, 19:00:37 UTC
- Prior SEC filing
- 11 Jun 2024
- Next SEC filing
- 25 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Herriot Tabuteau, M.D., Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Saad filed Form 4 for Axsome Therapeutics, Inc. (AXSM) on 11 Sep 2024.
Change
- Previous filing in this sequence was filed on 11 Jun 2024.
- Current net transaction value: -$965,442.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXSM
transaction
Common Stock
Options Exercise
- Transaction value
- $40,429
- Shares
- +11,016
- Change %
- +110%
- Price
- $3.67
- Shares after
- 21,018
- Date
- 11 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
AXSM
transaction
Common Stock
Sale
- Transaction value
- $1,005,871
- Shares
- -11,016
- Change %
- -52%
- Price
- $91.31
- Shares after
- 10,002
- Date
- 11 Sep 2024
- Ownership
- Direct
- Footnotes
- F2, F3, F4
AXSM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 300
- Date
- 11 Sep 2024
- Ownership
- See explanation 5 below.
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXSM
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -11,016
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 11 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,016
- Exercise price
- $3.67
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this month.
Footnote F2
Such transaction was pursuant to a pre-approved 10b5-1 plan.
Footnote F3
Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
Footnote F4
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $90.25 and $92.90.
Footnote F5
Represents additional shares held indirectly by the Reporting Person prior to September 11, 2024 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.